Clinical Trial Update: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab plus rivoceranib versus camrelizumab as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Rivoceranib (rivoceranib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | Phase 2 | Status: COMPLETED